| Ytd | 6.00% | |
| 1y | -38.63% |
| Open | 5.57 | Prev Close | 5.60 | Low | 5.30 | High | 5.93 | Mkt Cap | 17.10M |
| Vol | 62.65K | Avg Vol | 412.98K | EPS | -17.71 | P/E | N/A | Forward P/E | -0.79 |
| Beta | 1.39 | Short Ratio | 0.65 | Inst. Own | 3.03% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 3.64 | 200-d Avg | 3.76 | 1yr Est | 7.50 |
ADIL News
GLEN ALLEN, Va., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adia
Gainers Innovative Eyewear (NASDAQ:LUCY) stock rose 63.6% to $1.12 during Monday's regular sess
Gainers INVO Fertility (NASDAQ:IVF) shares increased by 163.4% to $2.56 during Monday's pre-mar
Completed acquisition of Azora Therapeutics, adding AT177, a fully synthetic, oral, colon-targeted a
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 41.1% to $0.09 during Frida
GLEN ALLEN, Va., June 16, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adia
LUCID CAPITAL MARKETS analyst Elemer Piros initiates coverage on Adial Pharmaceuticals (NASDAQ:AD
About the TransactionsThe acquisition of Azora was structured as an asset acquisition pursuant to wh
- Acquisition of Azora and concurrent private placement positions the combined company to advance it
GLEN ALLEN, Va., May 11, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial
New U.S. utility patent application targeting patient populations with demonstrated heightened respo
GLEN ALLEN, Va. , April 27, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Ad
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL - Get Free Report) was the recipient of a large decrease i
Demonstration batch production achieves all prespecified test specifications for dissolution, conten
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL - Get Free Report) saw a large growth in short interest du
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL - Get Free Report) was the target of a significant drop in
Company Highlights Advanced Partnering Discussions as AD04 Advances Toward Phase 3 Company Highlight
Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Submission f
Adial Pharmaceuticals (NASDAQ: ADIL - Get Free Report) and Kaleido Biosciences (NASDAQ: KLDO - Get F
GLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adia
Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026 Common Stock Will Begin
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL - Get Free Report) was the target of a significant decreas
GLEN ALLEN, Va. , Nov. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adi
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL - Get Free Report) was the recipient of a significant decr
